NOVOMEDIX LLC
Oral small-molecule drug (NMLC) that activates AMPK, inhibits mTOR and IL-11 secretion to treat diabetic cardiovascular disease
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Total capital
- $7.7M
- Federal grants
- $4.4M
- 9 awards · 2016–2025
- Rank in peer group#81 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $3.3M
- 2 awards · Health and Human S
- Rank in Biotech#104 of 4373
- Granted patents
- 7
- 9 pending · first 2015
- Rank in peer group#11 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Arthrofibrosis control using small molecule inhibitors of interleukin-11$314K
- Federal contractHealth and Human S · SBIR Phase II - Enhanced Overall Survival In High-risk Pediatric Solid Tumors Using A Novel Oral Small Molecule$3M
- Federal grantHealth and Human S · Phase I · Novel oral small molecules for progressive pulmonary fibrosis$307K
- Federal grantHealth and Human S · Phase II · Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$931K
- Federal grantHealth and Human S · Phase II · Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$1.1M
- Federal contractHealth and Human S · SBIR Concept Award To Novomedix- Novel Small Molecules For The Treatment Of Rhabdomyosarcoma$355K
- Federal grantHealth and Human S · Phase I · Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease$375K
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase I · Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease$375K
- Federal grantHealth and Human S · Phase I · Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$375K
- Federal grantHealth and Human S · Phase I · Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$375K
- Federal grantHealth and Human S · Phase I · Novel antifibrotic small molecules for the treatment of heart failure$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#81 · top 16%
- Granted patents#11 · top 2%
- Linked publications#20 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 7 granted of 16- GrantedSubstituted Biaryl Sulfonamides And The Use ThereofUSPTOUS 11,713,293
- PendingBiarylsulfonamides And Pharmaceutical Compositions Thereof, And Their Use For Treating Fibrotic Lung DiseaseUSPTOApplication 17999843
- GrantedNitrite Salts Of 1,1-DIMETHYLBIGUANIDE, Pharmaceutical Compositions, And Methods Of UseUSPTOUS 10,988,442
Show all 16 patent records
- Substituted Biaryl Sulfonamides And The Use ThereofAug 1, 2023 · US 11,713,293Granted
- Biarylsulfonamides And Pharmaceutical Compositions Thereof, And Their Use For Treating Fibrotic Lung DiseaseJun 29, 2023 · Application 17999843Pending
- Nitrite Salts Of 1,1-DIMETHYLBIGUANIDE, Pharmaceutical Compositions, And Methods Of UseApr 27, 2021 · US 10,988,442Granted
- Substituted Biaryl Sulfonamides And The Use ThereofFeb 27, 2020 · Application 16674943Pending
- Substituted Biaryl Sulfonamides And The Use ThereofNov 15, 2018 · Application 16046893Pending
- Substituted Biaryl Sulfonamides And The Use ThereofAug 7, 2018 · US 10,040,757Granted
- Furanyl Compounds And The Use ThereofMay 30, 2017 · US 9,663,483Granted
- Substituted Biaryl Sulfonamides And The Use ThereofMar 28, 2017 · US 9,604,924Granted
- Substituted Biaryl Sulfonamides And The Use ThereofOct 13, 2015 · US 9,156,781Granted
- Furanyl Compounds And The Use ThereofOct 6, 2015 · US 9,149,527Granted
- Substituted Biaryl Sulfonamides And The Use ThereofApplication PCTUS2013072303Pending
- Nitrite Salts Of 1,1-DIMETHYLBIGUANIDE, Pharmaceutical Compositions, And Methods Of UseApplication PCTUS2017060541Pending
- Furanyl Compounds And The Use ThereofApplication PCTUS2011039377Pending
- Biarylsulfonamides And Pharmaceutical Compositions Thereof, And Their Use For Treating Fibrotic Lung DiseaseApplication 63032361Pending
- Biarylsulfonamides And Pharmaceutical Compositions Thereof, And Their Use For Treating Fibrotic Lung DiseaseApplication PCTUS2021035067Pending
- Nitrite Salts Of 1,1-DIMETHYLBIGUANIDE, Pharmaceutical Compositions, And Methods Of UseApplication 62419892Pending
Recent research by its founders
- Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma20260 cites
- Novel Interleukin-11 Inhibitors Attenuate Collagen Production in Patient-Derived Synovial Fibroblasts20250 cites
- Abstract 3341: Targeting CXCR4 via the small molecule inhibitor NMX1 as a therapeutic strategy to treat high-risk malignancies20240 cites
Related companies, and why
- Helix, Inc.Similar federal contract value in Biotech · $3.6M in contracts
- ABVACC, INC.Similar federal contract value in Biotech · $3.5M in contracts
- DNASTAR, INC.Similar federal contract value in Biotech · $3.4M in contracts
- SynthegoSimilar federal contract value in Biotech · $3.2M in contracts
- NEOVAXSYN INCSimilar federal contract value in Biotech · $3.2M in contracts
- BOLDER BIOTECHNOLOGY INCSimilar federal contract value in Biotech · $3.1M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .